Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET
Company Participants
Brian M. Culley – CEO, President & Director
Ioana C. Hone – Director of Investor Relations
Jill Ann Howe – CFO & Principal Financial and Accounting Officer
Conference Call Participants
Jack Kilgannon Allen – Robert W. Baird & Co. Incorporated, Research Division
Jason Wesly McCarthy – Maxim Group LLC, Research Division
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Madison Britt Wynne El-Saadi – B. Riley Securities, Inc., Research Division
Sean McCutcheon – Raymond James & Associates, Inc., Research Division
Operator
Welcome to the Lineage Cell Therapeutics Second Quarter 2025 Conference Call. [Operator Instructions] An audio webcast of this call is available on the Investors section of Lineage’s website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage, and recordings, reproductions or transmissions of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today’s call is being recorded.
I would now like to introduce your host for today’s call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead.
Ioana C. Hone
Thank you, Desiree. Good afternoon and thank you for joining us. A press release reporting our second quarter 2025 financial results was issued earlier today, August 12, 2025, and can be found on the Investors section of our website.
Please note that, today’s remarks and responses to your questions reflect management’s views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties.
The company’s actual results or performance may differ materially from the
Read the full article here